Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Schizophenia DisorderMajor Depression DisordersSchizoaffective DisorderBipolar
Interventions
DRUG

Remimazolam

Remimazolam is a recently approved medication used for the induction of general anesthesia and maintenance of sedation. There have been no prior studies using remimazolam for the induction of anesthesia in ECT, and this research aims to investigate the feasibility of using remimazolam as an induction agent for ECT.

DRUG

Etomidate

Etomidate is widely used in ECT due to its rapid onset, stable hemodynamic profile, and quick recovery. In this study, remimazolam will be used as the experimental group, while etomidate will serve as the control group.

Trial Locations (1)

31116

Dankook University Hospital, Cheonan

All Listed Sponsors
lead

Yeongseok Yun

OTHER

NCT06664138 - Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment | Biotech Hunter | Biotech Hunter